The growth of <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crcY</i>, and DLL-Δ<i>crcZ</i> on LB medium. द्वारा Shuang Li (146392)

विषय:

Aggregated results for reported benefits and harms, stratified by leaflets and booklets. द्वारा Maren Dreier (628959)

“…<p>The figure indicates whether a leaflet contains <u>any</u> information on the benefits of CRC screening a) in general or specifically for b) colonoscopy or c) the FOBT, and whether it contains any information on the d) general and e) specific harms of colonoscopy. To be rated positive for harms, it was not sufficient if the only information about possible harms referred to pain, stating incorrectly that there is no pain involved.…”

Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. द्वारा Diana M. Hendrickx (1507435)

Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. द्वारा Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. द्वारा Diana M. Hendrickx (1507435)

Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. द्वारा Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. द्वारा Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. द्वारा Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. द्वारा Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. द्वारा Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... द्वारा Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. द्वारा Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. द्वारा Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... द्वारा Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB. द्वारा Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determin... द्वारा Diana M. Hendrickx (1507435)

Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB. द्वारा Diana M. Hendrickx (1507435)

Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study. द्वारा Diana M. Hendrickx (1507435)

Aerosol Capture for Coupling to Microfluidics: A Miniaturized Low-Cost Device for Size-Resolved Particle Collection द्वारा Yao Xiao (227567)

Recording Harms in Behavioural change Intervention Trials (RHABIT) Project Protocol द्वारा Diana Papaioannou (2758093)

“…It consists of 4 work packages (WP): WP1 Scoping review of literature to identify definitions, typologies, instruments, and suggested principles for recording harms in behavioural change intervention (BCI) trials; WP2 Qualitative interviews with clinical trials unit (CTU) and NIHR investigators involved in designing and delivering BCI trials; WP3 Workshop(s) to review guidance for recording harms in BCI trials; and WP4 Suggested principles and considerations for harms recording in BCI trials.…”